Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy by Huang, N. et al.
RESEARCH Open Access
Deletion of Nlrp3 protects from
inflammation-induced skeletal muscle
atrophy
Nora Huang1,2†, Melanie Kny1†, Fabian Riediger1,3†, Katharina Busch1, Sibylle Schmidt1, Friedrich C. Luft1,4,
Hortense Slevogt5,6 and Jens Fielitz1,2,4*
* Correspondence:
jens.fielitz@charite.de
†Equal contributors
1Experimental and Clinical Research
Center (ECRC),
Charité-Universitätsmedizin Berlin,
Max Delbrück Center (MDC) for
Molecular Medicine in the
Helmholtz Association, Berlin,
Germany
2Department of Cardiology, Heart
Center Brandenburg and Medical
University Brandenburg (MHB),
Bernau, Germany
Full list of author information is
available at the end of the article
Abstract
Background: Critically ill patients develop atrophic muscle failure, which increases
morbidity and mortality. Interleukin-1β (IL-1β) is activated early in sepsis. Whether IL-
1β acts directly on muscle cells and whether its inhibition prevents atrophy is
unknown. We aimed to investigate if IL-1β activation via the Nlrp3 inflammasome is
involved in inflammation-induced atrophy.
Methods: We performed an experimental study and prospective animal trial. The
effect of IL-1β on differentiated C2C12 muscle cells was investigated by analyzing
gene-and-protein expression, and atrophy response. Polymicrobial sepsis was
induced by cecum ligation and puncture surgery in Nlrp3 knockout and wild type
mice. Skeletal muscle morphology, gene and protein expression, and atrophy
markers were used to analyze the atrophy response. Immunostaining and reporter-
gene assays showed that IL-1β signaling is contained and active in myocytes.
Results: Immunostaining and reporter gene assays showed that IL-1β signaling is
contained and active in myocytes. IL-1β increased Il6 and atrogene gene expression
resulting in myocyte atrophy. Nlrp3 knockout mice showed reduced IL-1β serum
levels in sepsis. As determined by muscle morphology, organ weights, gene
expression, and protein content, muscle atrophy was attenuated in septic Nlrp3
knockout mice, compared to septic wild-type mice 96 h after surgery.
Conclusions: IL-1β directly acts on myocytes to cause atrophy in sepsis. Inhibition of
IL-1β activation by targeting Nlrp3 could be useful to prevent inflammation-induced
muscle failure in critically ill patients.
Keywords: Sepsis, IL-1β, Muscle weakness, ICUAW
Background
A major contributor of intensive care unit (ICU)-acquired weakness (ICUAW) is a se-
vere and disabling muscle atrophy leading to loss in strength and mass [1–4]. ICUAW
is associated with increased morbidity and mortality and has a significant impact on
healthcare systems [5, 6]. Sepsis and systemic inflammation are major risk factors for
ICUAW [7, 8]. Importantly, inflammation and acute-phase response occur early and
directly in muscle and affect disease progression in ICUAW. Recently, others and we
reported an imbalanced protein homeostasis caused by increased protein degradation
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and reduced protein synthesis in the skeletal muscle [4, 9–11]. Muscular-motor protein
breakdown, especially myosin heavy chain (MyHC), via the protein degrading ubiquitin
proteasome system (UPS), is a prominent feature of muscle atrophy [1, 4, 10–13]. The E3
ligase, muscle RING finger (MuRF) 1 (TRIM63), and F-box protein atrogin 1 (FBXO32)
are increased in muscle during atrophy and mediate degradation of structural pro-
teins [4, 10]. Interleukin-1β (IL-1β) is one of the most activated cytokines in sep-
sis [14–20]. In muscle, IL-1β increases MuRF1 and atrogin 1 expression
implicating a function in atrophy [21–23]. However, if IL-1β directly causes
muscle atrophy in sepsis and if inhibition of IL-1β prevents this response is un-
known. IL-1β production and secretion requires three consecutive steps that are
tightly controlled, namely expression, cleavage, and secretion. Whereas inflamma-
tory cytokines increase expression of pro-IL-1β, which is the inactive proform of
IL-1β, its conversion to IL-1β, and its secretion is mediated by caspase-1 activat-
ing inflammasomes [14, 24–28]. Inflammasomes are multi-protein complexes of
the innate immune system [29] and involved in the pathogenesis of sepsis [30].
Cytoplasmic receptors of the nucleotide binding domain (NOD)-like receptor
(NLR) family are key components of the inflammasome, of which the best char-
acterized NLR is NLRP3 [31, 32]. The NLRP3 inflammasome regulates maturation
and secretion of IL-1β [32]. IL-1β signal transduction occurs via the IL-1 recep-
tor, which is associated with IL-1 receptor-associated kinase 1 (IRAK1) that acti-
vates the transcription factor nuclear factor-kappa B (NF-κB) [33]. NLRP3 is
contained in muscle, and its activity is increased in myopathies [34]. However,
the function of NLRP3 and IL-1β in ICUAW is unknown. We tested the hypoth-
esis that IL-1β, depending on the Nlrp3 inflammasome, contributes to
inflammation-induced atrophy in vitro and in vivo.
Methods
Animal model
Animal procedures were performed in accordance with the guidelines of the Max-
Delbrück Center for Molecular Medicine, were approved by the Landesamt für
Gesundheit und Soziales, Berlin, Germany (G207/13, G129/12), and followed the
“Principles of Laboratory Animal Care” (NIH publication No. 86-23, revised 1985)
and the current version of German Law on the Protection of Animals. Nlrp3
knockout (KO) mice were kindly provided by Aubry Tardivel and Nicolas Fasel
(University of Lausanne) [35]. Cecal ligation and puncture (CLP) surgery was
performed to induce polymicrobial sepsis in 12- to 16-week-old male Nlrp3 KO or
wild-type (WT) mice as recently described [36–38]. Sham mice were treated identi-
cally except for the ligation and puncture of the cecum. Mice were sacrificed 96 h
after surgery. For more information, see Additional file 1.
Molecular and cell biology analysis
For detailed information about quantitative RT-PCR (qRT-PCR), western blotting,
immunostaining, and cell culture, see Additional file 1. Measurements of serum IL-1β
were performed by using the Mouse ELISA Kit for IL-1β (Abcam, ab100704) according
to the manufacturers’ protocol.
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Statistical tests
All experiments were performed independently and at least three times using biological
triplicates each. All qRT-PCR gene expression data from mouse and cell culture
samples was analyzed by one-way ANOVA with post hoc correction (Tukey’s post-
comparison test). Paired t test was used to study the distribution of myotube diameter
in C2C12 myotubes. Survival curves were compared with a Mantel-Cox test. Differences
were considered statistically significant at p < 0.05. Data are shown as mean ± standard
error of the mean (SEM) in bar plots. Plots and statistics calculation were done by using
the GraphPad Prism® 6 program (GraphPad Software, La Jolla, CA, USA), Adobe Illustra-
tor CS6, version 16.0.0, and Photoshop CS6, version 13.0. The documentation of
immunofluorescence and histological staining results was performed with a Leica fluores-
cence microscope using Leica cameras (DFC 360 FX and DFC 425) and the LAS.AF
software (version: 2.4.1 build 6384 and the LAS3.1 software (version 2.5.0.6735).
Results
IL-1β induces myocyte atrophy in vitro
Recently, we showed that inflammation and acute-phase response participates in the
pathogenesis of ICUAW in patients [10]. However, whether IL-1β is synthesized in
muscle and whether Nlrp3-mediated IL-1β maturation is involved in inflammation-
induced atrophy was unknown. We performed qRT-PCR to investigate if sepsis
increases Il1b or Nlrp3 expression in gastrocnemius/plantaris or tibialis anterior
muscle of mice and found that sepsis induced Il1b and Nlrp3 expression in both
muscles (Additional file 2A, B). Il6 expression was also induced. These data indicate
that IL-1β and Nlrp3 are contained and activated in muscles during sepsis.
To investigate if the IL-1β signaling pathway is contained and active in myocytes, we
analyzed cytoplasmic-to-nuclear translocation of IL-1 receptor type I (IL-1R1) associ-
ated kinase 1 (IRAK-1) in C2C12 muscle cells. C2C12 myoblasts were originally iso-
lated from wild-type mice [39] and selected for its ability to differentiate to myotubes
expressing characteristic muscle proteins [40]. Others [41–43] and we [36, 38, 44] have
used this cell line earlier to investigate mechanisms of inflammation-induced myocyte
atrophy. Using immunocytochemistry, we found that 30 min of IL-1β treatment
resulted in an increased cytoplasmic-to-nuclear shift of IRAK-1 in C2C12 myocytes
(Fig. 1a) indicating that the IL-1β pathway is active in myocytes. Since IL-1β mediates
its effects via NF-κB in non-myocytes, a luciferase reporter assay was used to test if this
response also occurs in myocytes. The same assay performed in HeLa cells was used as
positive control. IL-1β treatment induced the NF-κB promoter in muscle and non-
muscle cells (Fig. 1b), indicating that IL-1β activates NF-κB dependent signaling events
in muscle cells. To test if IL-1β induces its target genes in myocytes, we treated C2C12
myotubes with recombinant IL-1β for different time points and quantitated Il6 expres-
sion (Fig. 1c). IL-1β induced Il6 and Nlrp3 expression in myocytes after 2 h of treat-
ment (Fig. 1c, d). Together, these data indicate that the IL-1β pathway is functional in
myocytes. To investigate if IL-1β induces myocyte atrophy, we treated C2C12 myotubes
with increasing amounts of recombinant IL-1β and vehicle, respectively, for 72 h and
measured myotube diameters. IL-1β treatment caused a significant reduction of
myotube diameters after 72 h (Fig. 1e). Frequency distribution histograms of myotube
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diameters showed a dose-dependent increase in the number of thinner myotubes
resulting in a leftward shift of the histogram and a dose-dependent decrease in mean
myotube diameters after 72 h of treatment (Fig. 1f, h). Dexamethasone (Dexa), which
was used as positive control, resulted in myotube atrophy after 72 h (Fig. 1e, g, h).
Because a reduction in MyHC proteins is consistently observed in inflammation-
induced atrophy [1, 10], we investigated if IL-1β causes a reduction in MyHC protein.
C2C12 myotubes were treated with recombinant IL-1β and vehicle, respectively, for
72 h and Western blot was performed. Indeed, IL-1β decreased fast and slow MyHC
protein contents (Fig. 2a). As expected, Dexa treatment caused a reduction in slow and
fast MyHC contents after 72 h (Fig. 2a). Recently, we reported that inflammation-
induced atrophy is caused by a dysregulation in protein homeostasis with decreased
MyHC expression and increased UPS-dependent MyHC degradation [10]. Therefore,
we investigated if IL-1β causes a reduction in MyHC expression. C2C12 myotubes were
treated with IL-1β and vehicle, respectively, for 24 h and Myh2, 4, and 7 expression,
encoding fast/type IIa, fast/type IIb and slow/type I MyHC, respectively, was quanti-
tated by qRT-PCR (Fig. 2b). IL-1β treatment led to a decreased Myh2, Myh4, and Myh7
expression after 24 h; whereas Dexa led to an increased Myh4 and Myh7 but not Myh2
expression (Fig. 2b). To test if IL-1β activates atrophy gene expression involved in
MyHC degradation, we treated C2C12 myotubes with IL-1β for 2 h and quantitated
Trim63 and Fbxo32 expression by qRT-PCR. IL-1β significantly increased Trim63 and
Fbxo32 expression, indicating that MuRF1 and atrogin 1 are involved in IL-1β-induced
atrophy. Likewise, Dexa treatment increased Trim63 and Fbxo32 expression in myo-
cytes (Fig. 2c). These data indicate that IL-1β causes a disturbed protein homeostasis
contributing to IL-1β mediated atrophy.
Nlrp3 KO mice are protected against inflammation-induced atrophy
At baseline, Nlrp3 KO were indistinguishable from WT mice and did not differ in body,
liver, spleen, or skeletal muscle weights normalized to tibia length (Additional file 3A–C).
To investigate whether or not Nlrp3 inflammasome-dependent IL-1β activation affects
inflammation-induced atrophy, we subjected male Nlrp3 KO and WT mice to CLP (Nlrp3
KO, n = 27; WT, n = 33) or sham surgery (Nlrp3 KO, n = 11; WT, n = 16), respectively.
Compared to WT mice, significantly less Nlrp3 KO mice died after 96 h after CLP surgery
(See figure on previous page.)
Fig. 1 The IL-1β signaling pathway is contained and active in C2C12 myocytes. a C2C12 muscle cells were
treated with human recombinant IL-1β (10 ng/ml) or vehicle for 30 min and 1 h. Immunocytochemistry
with anti-IRAK1 antibody shows cytoplasmic-to-nuclear translocation of IRAK1 in response to IL-1β after
30 min. Nuclei were stained in blue (DAPI). Scale bar = 50 μm. b Synthetic luciferase reporters with
multimerized NF-κB sites (NF-κB-Luc) were transfected into C2C12 (b, left panel) and HeLa (b, right panel)
cells, together with LacZ as transfection control. Cells were treated with recombinant IL-1β (10 ng/ml) for
24 h. n = 3. c, d C2C12 cells were differentiated for 8 days and treated with human recombinant IL-1β
(10 ng/ml) for different time points as indicated. qRT-PCR analysis of Il6 and Nlrp3. mRNA expression was
normalized to Gapdh. All data are reported as fold change ± SEM. e–h IL-1β increases Nlrp3 expression and
induces atrophy in differentiated C2C12 myocytes in vitro. C2C12 cells were differentiated for 8 days and
treated with human recombinant IL-1β (10, 20, and 50 ng/ml) for 72 h. Dexamethasone (10 μM/ml)
treatment was used as atrophy control. e Representative light microscopy pictures. Scale bar = 250 μm. f, g
Frequency distribution histograms of cell width of IL-1β (10, 20, and 50 ng/ml) and dexamethasone-treated
myotubes, as indicated, compared to vehicle-treated myotubes, n = 100 cells per condition. h Mean
myotube width. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001
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(57.6 vs. 29.6%; p < 0.05) (Fig. 3a). Septic WT mice showed a reduction in body and liver
weight and no change in spleen weight (Fig. 3b; Additional file 4A, B). In contrast,
Nlrp3 KO did not lose body or liver weight, while spleen weight increased in these
mice during sepsis (Fig. 3b; Additional file 4A, B). We investigated if absence of Nlrp3
affects muscular cytokine expression in sepsis. At baseline, Il6 expression was not
different between Nlrp3 KO and WT in gastrocnemius/plantaris and tibialis anterior
(Additional file 5A). CLP did not or only marginally induce muscular Il6 expression
in Nlrp3 KO compared to WT (Fig. 3c, d). Also, Il1b expression was not different
between Nlrp3 KO and WT at baseline, and its expression was blunted in muscles of
CLP-treated Nlrp3 KO compared to WT mice (Additional file 6A, B). CLP induced Nlrp3
expression in WT but not in Nlrp3 KO (Additional file 6C, D). Since conversion of pro-
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IL-1β to IL-1β depends on an intact Nlrp3 inflammasome [14, 24, 25], we quantitated IL-
1β cytokine levels in the serum of Nlrp3 KO and WT. Already at baseline, IL-1β serum
levels were reduced in Nlrp3 KO compared to WT (Additional file 6E). CLP significantly
induced IL-1β serum levels in WT. This induction in IL-1β serum levels was greatly
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reduced in Nlrp3 KO (Additional file 6F). These data indicate that in sepsis muscular Il1b
and Il6 expression depend on Nlrp3.
Compared to WT sham, WT CLP mice showed a significant reduction in the
weights of all muscles investigated 96 h after surgery. In contrast, the reduction of
muscle mass of Nlrp3 KO CLP compared to Nlrp3 KO sham mice was less severe
WT
**** **
****WT Sham
WT CLP
0 1000 2000 3000 4000
0
10
20
30
40
50
MCSA [µm2] 
****
0 1000 2000 3000 4000
0
10
20
30
40
50
MCSA [µm2] 
**
0
500
1000
1500
2000
2500
**** **
****
0
500
1000
1500
2000
2500
 M
C
S
A
 [µ
m
2 ]
 
0 1000 2000 3000 4000
0
10
20
30
40
50
MCSA [µm2] 
fr
eq
u
en
cy
 [%
]
WT Sham
WT CLP
****
0 1000 2000 3000 4000
0
10
20
30
40
50
MCSA [µm2] 
**
Nlrp3-/- Sham
Nlrp3-/- CLP
 M
C
S
A
 [µ
m
2 ]
 
fr
eq
u
en
cy
 [%
]
fr
eq
u
en
cy
 [%
]
fr
eq
u
en
cy
 [%
]
b
WT Nlrp3-/-
CLP - -+ +
WT Nlrp3-/-
CLP - -+ +
WT Nlrp3-/-
mahsmahs PLCPLC
H
E
A
T
P
as
e
H
E
A
T
P
as
e
G
as
tr
o
cn
em
iu
s/
P
la
n
ta
ri
s
Ti
bi
al
is
 a
nt
er
io
r
a
Nlrp3-/- Sham
Nlrp3-/- CLP
Ti
bi
al
is
 a
nt
er
io
r
Fa
st
 / 
ty
pe
 II
 fi
br
es
G
as
tr
o
cn
em
iu
s/
P
la
n
ta
ri
s
Fa
st
 / 
ty
pe
 II
 fi
br
es
Fig. 4 Nlrp3 KO mice are protected from inflammation-induced muscle atrophy. 12–16-week-old male Nlrp3 KO
and WT mice were subjected to CLP or sham surgery. a H&E and ATPase stain of histological cross sections from
gastrocnemius/plantaris (GP) and tibialis anterior (TA) muscle from sham and CLP-operated WT and Nlrp3 KO mice
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(Fig. 3e, f, Additional file 4C, D). These data indicate that Nlrp3 KO mice are pro-
tected against inflammation-induced atrophy. Since inflammation-induced atrophy
predominantly affects fast-twitch fibers in critically ill patients [10], we analyzed at-
rophy of fast/type II fibers in gastrocnemius/plantaris and tibialis anterior muscles
of Nlrp3 KO and WT after CLP. The histological pictures show that myofibers of
WT but not of Nlrp3 KO CLP atrophied during sepsis (Fig. 4a). Accordingly, fre-
quency distribution histograms of the myocyte cross sectional areas (MCSA)
showed an increased number of smaller fast/type II fibers in both muscles of septic
WT but not Nlrp3 KO leading to a leftward shift of the distribution curve (Fig. 4b).
This atrophic response was attenuated in Nlrp3 KO compared to WT following
sepsis as indicated by a less pronounced reduction in mean MCSA in septic Nlrp3
KO (Fig. 4b). These data indicate Nlrp3 contributes to fast/type II fiber atrophy in
sepsis.
To test if inflammatory atrophy was accompanied by a reduction in MyHC, Western
blot analysis was performed and showed that sepsis caused a reduction of slow and fast
MyHC protein in gastrocnemius/plantaris and tibialis anterior of WT but not Nlrp3
KO (Fig. 5a). To elucidate if decreased myosin content was due to a reduction in
MyHC gene expression, we quantitated Myh2, 4 and 7 by qRT-PCR. Inflammation
caused a significant reduction in Myh2 and Myh7 gene expression in WT gastrocne-
mius/plantaris muscle (Fig. 5b). In contrast, Myh2 and Myh7 expression increased in
Nlrp3 KO gastrocnemius/plantaris muscle during inflammation (Fig. 5b). Inflammation
did not affect Myh4 gene expression. In the tibialis anterior muscle, Myh2 gene expres-
sion was regulated with the same trend as in gastrocnemius/plantaris, whereas Myh4
and Myh7 did not show a significant regulation (Additional file 7). To test if decreased
myosin content was correlated with increased atrogene expression, we quantitated
Trim63 and Fbxo32 expression in the muscle. Indeed, Trim63 and Fbxo32 expression
were significantly increased in septic WT but remained unchanged in Nlrp3 KO
muscles (Fig. 5c–f ). Western blot analysis showed that MuRF1 protein expression was
increased in gastrocnemius/plantaris of WT CLP but not in Nlrp3 KO CLP (Fig. 5a).
These data indicate that decreased Myh gene expression and its increased degradation
contribute to inflammation-induced atrophy.
Discussion
ICUAW is a devastating disease warranting detailed mechanistic investigation [2, 45].
In our study, we found a close relationship between systemic inflammation in sepsis
and muscle atrophy. We show that IL-1β signaling is present in myocytes and when
activated leads to myocyte atrophy in vitro. Germline deletion of Nlrp3 in mice led to
reduced IL-1β serum levels in response to inflammation and less inflammation-induced
muscle atrophy in vivo. These data underscore the conclusion that during inflamma-
tion, skeletal muscle and myocytes are targeted by IL-1β to undergo atrophy. However,
since Nlrp3 is ubiquitously expressed [31, 32], the observed reduction in IL-1β serum
levels in response to inflammation was most likely caused by the absence of Nlrp3 in
multiple cells, tissues, and organs and not only muscle. Nevertheless, our findings
suggest Nlrp3 as target for treatment against inflammation-induced atrophy.
Based on earlier published work, we suggest that muscle contributes to inflammation
and acute-phase response. Of note, the acute-phase response protein serum amyloid
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A1 (SAA1) was shown to be synthesized by and released from muscle of critically ill
patients and septic mice [36]. SAA1 induces IL-1β expression [46] and secretion [47]
and activates the Nlrp3 inflammasome in immune cells [46]. The Nlrp3 inflammasome
is contained and active in C2C12 myocytes [48]. IL-1β induces atrogene expression in
myocytes [23]. Together, these data suggest feedback loops between IL-1β, IL6, SAA1,
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and Nlrp3 during inflammation reinforcing muscle atrophy in critical illness. Here, we
show that Il1b and Il6 as well as Nlrp3 expression are increased in muscles of septic
mice. We show that the IL-1β signaling pathway is contained and active in myocytes in
vitro. Based on these observations, it is possible that Nlrp3 KO mice have less overall
inflammation during sepsis when compared to Nlrp3 WT animals and that not only de-
creased IL-1β levels but also reduced overall inflammation contributed to reduced
muscle atrophy in septic Nlrp3 KO mice. However, since we did not perform a compre-
hensive analysis of inflammation in our mice, we cannot provide a definitive answer to
this hypothesis.
We hypothesized that activation of the Nlrp3 inflammasome plays a role in
inflammation-mediated muscle atrophy via activation of IL-1β. The Nlrp3 inflamma-
some is activated by pathogen-associated molecular patterns [49] and host-derived
molecules, such as DNA, which indicates cellular damage and cell death, so-called
damage-associated molecular patterns [50]. Nlrp3 inflammasome could therefore
contribute to both pathogen-associated immune responses and sterile-inflammation.
We found that depletion of Nlrp3 in mice not only increases their survival in sepsis but
also inhibits sepsis and inflammation-mediated muscle atrophy. We believe that this
phenotype is predominantly caused by the missing conversion of pro-IL-1β to IL-1β.
We demonstrate that IL-1β induces atrophy presumably via the IL-1 signaling pathway
leading to NF-κB activation and increased MuRF1 and atrogin 1 expression in vitro.
This interpretation is in line with published work showing that IL-1β increases
atrogene expression in vitro [23]. Likewise, decreased activation of IL-1β in Nlrp3 KO
mice during sepsis resulted in decreased Il6 expression, which is a target of IL-1β and
mediates atrophy [36, 51]. We hypothesize that blockage of Nlrp3 inhibits sensing of
pathogen and host signals, which is followed by inhibition of IL-1β- and IL-6-
dependent damage pathways resulting in better survival and reduced muscle atrophy.
IL-6 and SAA1 mRNA and protein expression are increased in muscle of critically ill
patients [7, 36]. These factors promote continuous inflammation and acute-phase
response that in turn triggers ICUAW. We observed that IL-1β induces Il6 and Nlrp3
expression in cultured myocytes. After 24 h of treatment, expression levels of both
genes dropped. In contrast, in septic mice, the muscular expression of Il6 mRNA is still
markedly increased after 96 h post CLP, reflecting the situation of critically ill patients.
Our data add IL-1β and Nlrp3 as further cytokine network factors, highly expressed in
the skeletal muscle during systemic inflammation. The observed differences between
cultured myocytes and muscle tissue could be explained by the fact that a functional
cytokine network relies on interacting organs rather than cell-to-cell communications
within an isolated organ. This interpretation implies that the muscle, although itself an
immune organ, requires interaction and feedback from other organs to fully respond to
systemic inflammation. Taken together, during systemic inflammation, muscular
expression of SAA1, IL-6, Nlrp3, and IL-1β is persistently elevated, which might
contribute to atrophy.
An imbalanced muscular protein homeostasis plays a dominant role in muscle failure
of critically ill patients [4, 10, 38]. Atrogin 1 and MuRF1 are key “atrogenes” in this
process [10, 22, 38, 52]. Our finding that atrogene expression was not increased in
Nlrp3 KO indicates that atrogene expression is regulated by Nlrp3-dependent IL-1β
activation. Muscle atrophy is accompanied by increased MyHC degradation and
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decreased MyHC expression [10]. Whereas sepsis led to a decreased Myh2 and Myh7
expression in muscle of WT, this effect was blunted in Nlrp3 KO. Because IL-1β treat-
ment leads to decreased Myh2, Myh4, and Myh7 expression in myocytes, reduced
muscular MyHC expression during sepsis might be caused by IL-1β. Our data indicate
that Nlrp3-mediated IL-1β activation may affect both major branches of protein
homeostasis and therefore regulate MyHC synthesis via mRNA expression as well as
UPS-mediated MyHC degradation.
Conclusions
We suggest that Nlrp3-mediated IL-1β activation in sepsis is a major pathogenic
mechanism in inflammatory muscle atrophy. Inhibition of IL-1β could be useful to
prevent ICUAW in critically ill patients. Since not only sepsis is associated with
inflammation-induced muscle failure and increased IL-1β levels other forms of muscle
atrophy might also profit from Nlrp3/IL-1β inhibition; for example, in patients with
rheumatoid arthritis and inflammatory bowel disease. However, IL-1β is only one of
many cytokines that are elevated during the cytokine storm in the acute phase of sepsis.
It was shown that IL-1β, TNF-α, and IFN-γ were below detection limit in patients with
septic shock admitted to an ICU [41]. In these patients, continuously high IL-6 serum
levels were measured. IL-6 was not only negatively associated with muscular myosin
contents, a marker for muscle atrophy, but also provoked atrophy in myocytes in vitro
[41]. These data indicate that inhibition of multiple cytokines as well as its correct
timing is important to reduce inflammation-induced atrophy. However, unlike during
controlled conditions in animal experiments, the precise time point of sepsis onset in
patients is often unknown which impedes such treatment decisions for the caring
clinician. The key to a targeted therapy of inflammation-induced atrophy in sepsis is,
therefore, a better characterization of the disease process, and we think that animal
models are helpful in this regard.
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qRT-PCR analysis of Nlrp3, IL-1β, and Il6 expression in gastrocnemius/plantaris (GP) and (B) tibialis anterior (TA)
muscles of sham (n = 5) and CLP (n = 5) mice 4 days after surgery. mRNA expression was normalized to Gapdh.
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (EPS 1161 kb)
Additional file 3: Body and organ weights of Nlrp3 KO and WT mice were indistinguishable at baseline. Weights
of body (A), liver and spleen (B), and muscle (C); gastrocnemius/plantaris (GP), tibialis anterior (TA), soleus (Sol) and
extensor digitorum longus (EDL)); Nlrp3 KO (n = 6); WT (n = 6). All weights were normalized to tibia length and
expressed as percent wise change compared to WT. Animals were 12–16-week-old males. Data are presented as
the mean ± SEM. ns = not significant. (EPS 1175 kb)
Additional file 4: Septic Nlrp3 KO mice show no decrease in liver weight but an increase in spleen weight.
Twelve- to 16-week-old male Nlrp3 KO and WT mice were subjected to CLP or sham surgery. Weights were
determined at 96 h after surgery. (A) Liver and (B) spleen weight. (C, D) Weights of the skeletal muscles (C)
soleus (Sol) and (D) extensor digitorum longus (EDL) (WT sham (n = 13), WT CLP (n = 12), Nlrp3 KO sham (n = 8),
Nlrp3 KO CLP (n = 16)). All weights were normalized to tibia length and expressed as percent wise change
compared to the respective sham group. Data are presented as the mean ± SEM. ns = not significant.
*p < 0.05; **p < 0.01; ***p < 0.001. (EPS 1427 kb)
Additional file 5: Baseline muscular Il6 and Il1b expression in Nlrp3 KO and WT mice. qRT-PCR analysis of (A) Il6
and (B) IL1b expression in gastrocnemius/plantaris (GP) and tibialis anterior (TA) muscles as indicated. Nlrp3 KO
(n = 6) and WT (n = 6). mRNA expression was normalized to Gapdh. Data are presented as the mean ± SEM.
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analysis of myosin heavy chain (Myh) 2, Myh4, and Myh7 expression in tibialis anterior (TA) muscles of sham (n = 5)
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KO: CLP n = 6). mRNA expression was normalized to Gapdh. Data are presented as mean ± SEM. ns, not significant;
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